



January 8, 2018

Livongo and Lilly Collaborate on Real-World Diabetes Research

Companies join forces to advance predictive and prescriptive recommendations for people with diabetes

INDIANAPOLIS and MOUNTAIN VIEW, Calif., Jan. 8, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Livongo Health, a leading consumer digital health company focused on empowering all people with chronic conditions to live better and healthier lives, today announced a strategic collaboration to study real-world evidence and develop new insights to reduce the burden on people living with diabetes.

The research collaboration will combine real-world behavioral studies and claims data to advance knowledge about effective interventions in diabetes care. The companies aim to contribute to medical literature in three areas:

1. Measure the impact of remote diabetes self-management education and support on clinical and healthcare cost outcomes
2. Understand drivers of healthy behaviors
3. Understand how people living with diabetes can stay more actively involved in their health

Lilly has been a leader in diabetes care for more than 90 years, and was the first company to make insulin commercially available to people with the disease. Today, Lilly provides a wide range of therapies to address the diverse needs of people living with diabetes.

"Collaborating with Livongo is an important step in our research efforts," said Sherry Martin, MD, vice president of Medical Affairs, Lilly Diabetes. "We hope that our combined expertise will play a key role in empowering people with diabetes to better manage their condition."

Livongo is redesigning chronic condition management, starting with diabetes. Livongo delivers a personalized experience, using data and clinical science, and helps to make staying healthy easier, which results in [measurable positive health outcomes for people with diabetes](#)¹ and [lower costs for payers](#)².

"These studies will have a direct impact on the lives of Livongo members," said Jennifer Schneider, MD, chief medical officer, Livongo. "Livongo uses reinforcement learning to create customized and actionable insights that guide people to better manage their diabetes. The knowledge we gain from these studies will be incorporated into our diabetes management platform to help drive better health outcomes for our members."

Livongo and Lilly aim to publish the results of their collaborative research studies to further advance diabetes care for people worldwide.

About Diabetes

Approximately 30 million Americans³ and an estimated 425 million adults worldwide have diabetes.⁴ More than one million children and adolescents have type 1 diabetes globally.⁴ Type 2 diabetes is the most common type internationally, accounting for an estimated 90 to 95 percent of all diabetes cases in the United States alone.³ Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.

About Livongo Health

Livongo has a vision of empowering all people with chronic conditions to live better and healthier lives. We are redesigning chronic condition management, starting with diabetes, by driving behavior change through the combination of consumer health technology, personalized recommendations, and real-time support at the point of impact. Powered by advanced analytics, we create personalized experiences for our members so they receive the right information, tools, and support, at the right time. Our approach is leading to better financial and clinical outcomes while creating a better experience for all people with chronic conditions and their care team of family, friends, and medical professionals. For more information visit: www.livongo.com.

About Lilly Diabetes

Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research, collaboration and quality manufacturing we strive to make life better for people affected by diabetes. We offer a wide range of therapies and a continued determination to provide real solutions—from medicines and technologies to support programs and more. For the latest updates, visit www.lillydiabetes.com or follow us on Twitter: [@LillyDiabetes](https://twitter.com/LillyDiabetes) and Facebook: [LillyDiabetesUS](https://www.facebook.com/LillyDiabetesUS).

About Eli Lilly and Company

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and www.lilly.com/newsroom/social-channels.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about a strategic initiative between Eli Lilly and Company and Livongo Health to study real world evidence and develop new insights to reduce the burden of people living with diabetes, and reflects Lilly's current belief. However, as with any research collaboration, there are substantial risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of this research collaboration. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

P-LLY

01/2018 Lilly USA, LLC 2018. All rights reserved.

References

1. Downing J, Bollyky J, Schneider J. Use of a Connected Glucose Meter and Certified Diabetes Educator Coaching to Decrease the Likelihood of Abnormal Blood Glucose Excursions: The Livongo for Diabetes Program. J Med Internet Res 2017;19(7):e234, DOI: 10.2196/jmir.6659
2. Presentation at the 77th Annual American Diabetes Association's Scientific Sessions.
3. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Available at: <https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf>. November 2017.
4. International Diabetes Federation. IDF Diabetes Atlas, 8th edn, 2017. Available at: <http://www.diabetesatlas.org/>. November 2017.

Refer to:

Theresa Champagne, press@livongo.com, 650-382-2909, (Livongo Media)

Jennifer Hoopingarner, jennifer.hoopingarner@lilly.com, 317-741-8811, (Lilly Media)

The Lilly logo is rendered in a vibrant red, cursive script font. The letters are fluid and interconnected, with a classic, elegant feel. The 'L' is particularly large and prominent, leading into the 'i', 'l', 'l', 'e', and 'y' which follow in a similar flowing style. The overall appearance is that of a handwritten signature or a stylized brand mark.



View original content with multimedia: <http://www.prnewswire.com/news-releases/livongo-and-lilly-collaborate-on-real-world-diabetes-research-300578410.html>

SOURCE Eli Lilly and Company; Livongo

News Provided by Acquire Media